Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Vergote I, et al. Among authors: marth c. Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7. Lancet Oncol. 2019. PMID: 31076365 Free article. Clinical Trial.
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
Boidot R, Blum MGB, Wissler MP, Gottin C, Ruzicka J, Chevrier S, Delhomme TM, Audoux J, Jeanniard A, Just PA, Harter P, Pignata S, González-Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Duforet-Frebourg N, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E; PAOLA-1/ ENGOT-ov25 Study Group. Boidot R, et al. Among authors: marth c. Eur J Cancer. 2024 May;202:113978. doi: 10.1016/j.ejca.2024.113978. Epub 2024 Mar 2. Eur J Cancer. 2024. PMID: 38471290
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.
Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE; CX.5 SHAPE investigators; CX.5 SHAPE Investigators. Plante M, et al. N Engl J Med. 2024 Feb 29;390(9):819-829. doi: 10.1056/NEJMoa2308900. N Engl J Med. 2024. PMID: 38416430 Free article. Clinical Trial.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. Ledermann JA, et al. Among authors: marth c. Ann Oncol. 2024 Mar;35(3):248-266. doi: 10.1016/j.annonc.2023.11.015. Epub 2024 Feb 1. Ann Oncol. 2024. PMID: 38307807
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F, Marth C, Henry S, Reuss A, Cibula D, Gaba Garcia L, Colombo N, Schmalfeld B, de Gregorio N, Wimberger P, Hasenburg A, Sehouli J, Gropp-Meier M, Schouten PC, Hahnen E, Hauke J, Polleis S, Harter P. Heitz F, et al. Among authors: marth c. Int J Gynecol Cancer. 2023 Dec 4;33(12):1966-1969. doi: 10.1136/ijgc-2023-004944. Int J Gynecol Cancer. 2023. PMID: 37935524 Clinical Trial.
Surgery and HIPEC in relapse for all patients with ovarian cancer?
Hasson SP, Ray-Coquard I, Marth C, Harter P. Hasson SP, et al. Among authors: marth c. ESMO Open. 2023 Dec;8(6):102052. doi: 10.1016/j.esmoop.2023.102052. Epub 2023 Nov 2. ESMO Open. 2023. PMID: 37922687 Free PMC article. No abstract available.
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, Boulouard F, Joly F, Boucly R, Dumont A, Basset N, Coulet F, Chevalier LM, Rouleau E, Leitner K, González-Martin A, Gargiulo P, Lück HJ, Genestie C; PAOLA-1 investigators; Ray-Coquard I, Pujade-Lauraine E, Vaur D. Leman R, et al. Clin Cancer Res. 2023 Nov 1;29(21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. Clin Cancer Res. 2023. PMID: 37756555 Free PMC article.
480 results